COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--HemoGenix announced publication of its White Paper on “Stem Cells and Predictive In Vitro Toxicity Testing,” an informative and different view of how stem cells can be used to predict potential toxicity in early stage drug development and help reduce the attrition rate, time and cost prior to human clinical trials. Several primary stem cell systems, such as blood-forming stem cells, are already used to provide a high degree of predictive value in toxicity testing. Embryonic (ES) and adult induced pluripotent stem (iPS) cells are considered to harness the hope of new therapies for many diseases. However, they also have the potential to provide the tools to develop drugs with improved safety and low toxic side effects, if they can be validated as alternative equivalents to primary stem cells.
